Regulation FD Disclosure

Odyssey Therapeutics, Inc. — Form 8-K Summary

Reporting date: October 20, 2026. This is an event-driven filing, not a quarterly or annual financial report. Odyssey is a Delaware corporation whose common stock trades on Nasdaq under ODTX.

Business context and event

Under Item 7.01, Odyssey announced that it issued a press release titled “Odyssey Therapeutics Presents Completed Phase 2a OD-001 Induction Results Strengthening Clinical Proof of Concept at UEG Week 2026” and posted an October 2026 corporate presentation. The press release and presentation are identified as Exhibits 99.1 and 99.2, but their contents are not included in the provided filing text.

Financial information

The filing text provides no revenue, profit, cash flow, margin, debt, liquidity, or other financial metrics, and no comparable-period figures.

Outlook, risks, and filing terms

The provided text contains no guidance, detailed management commentary, risk updates, or contingencies. The Item 7.01 information and exhibits are furnished, not deemed filed for purposes of Section 18 of the Exchange Act, and are not incorporated by reference except by specific reference in a subsequent filing.

Facts investors should verify

  • Review Exhibit 99.1 for the OD-001 Phase 2a induction results, including efficacy, safety, study design, and any limitations.
  • Review Exhibit 99.2 for additional clinical data, development plans, and any forward-looking statements.
  • Check subsequent filings for updates to the program, financial position, or stated risks.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.